Information on how to access Mylotarg™▼ (gemtuzumab ozogamicin) and cytarabine prescribing information and adverse event reporting can be found at the bottom of the page.
In this video, Dr. Tholouli discusses Mylotarg’s NICE approval and its practical approach to the issue of waiting for cytogenics and Mylotarg’s use1. Dr Tholouli also mentions results in event free survival and relapse risk alongside the safety data2. Practical considerations using the ALFA schedule, platelet recovery, risk of VOD and minimising risks to the liver are also considered2.
Dr. Eleni Tholouli is a Consultant Haematologist at Manchester University NHS Trust and Director of the Adult Stem Cell Transplant Unit. She is a member of the Haemato-Oncology Pathway Board at Manchester Cancer and of national bodies such as the AML Working Group and the Blood and Marrow Transplantation Clinical Reference Group. Her expertise covers a wide range of haemato-oncological malignancies and non-malignant disorders.
Watch Professor Robert Hills discuss the key clinical data from the pivotal ALFA study
Learn more
Download the Fast Facts PDF document to aid your understanding of MYLOTARG
View Fast Facts PDF
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. March 2021
Sign up now
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020
No